Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size, Share, Trends and Forecast 2022-2030

Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.

LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer-BioNTech COVID-19 vaccines).

In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.

Industry Insights

The global Liposomal and Lipid Nanoparticle Drug Delivery Systems market size is projected to reach US$ 8977.8 million by 2028, from US$ 4571.7 million in 2021, at a CAGR of 10.0% during 2022-2028.

Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Liposomal and Lipid Nanoparticle Drug Delivery Systems market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Liposomal and Lipid Nanoparticle Drug Delivery Systems Breakdown Data by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

Liposomal and Lipid Nanoparticle Drug Delivery Systems Breakdown Data by Application

Hospital

Retail Pharmacy

Other

Regional Analysis

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

1 Report Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Liposomes Drugs

1.2.3 Lipid Nanoparticle Drugs

1.3 Market by Application

1.3.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Application: 2017 VS 2021 VS 2028

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Perspective (2017-2028)

2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Growth Trends by Region

2.2.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Region (2017-2022)

2.2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2023-2028)

2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Dynamics

2.3.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Trends

2.3.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Drivers

2.3.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Challenges

2.3.4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Players by Revenue

3.1.1 Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Players by Revenue (2017-2022)

3.1.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2017-2022)

3.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue

3.4 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Concentration Ratio

3.4.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in 2021

3.5 Liposomal and Lipid Nanoparticle Drug Delivery Systems Key Players Head office and Area Served

3.6 Key Players Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Solution and Service

3.7 Date of Enter into Liposomal and Lipid Nanoparticle Drug Delivery Systems Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Breakdown Data by Type

4.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Type (2017-2022)

4.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2023-2028)

5 Liposomal and Lipid Nanoparticle Drug Delivery Systems Breakdown Data by Application

5.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Application (2017-2022)

5.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2017-2028)

6.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2017-2022)

6.3 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2023-2028)

6.4 United States

6.5 Canada

7 Europe

7.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2017-2028)

7.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2017-2022)

7.3 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2023-2028)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2017-2028)

8.2 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2017-2022)

8.3 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2023-2028)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

9 Latin America

9.1 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2017-2028)

9.2 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2017-2022)

9.3 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2023-2028)

9.4 Mexico

9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2017-2028)

10.2 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2017-2022)

10.3 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2023-2028)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

11 Key Players Profiles

11.1 Johnson & Johnson

11.1.1 Johnson & Johnson Company Detail

11.1.2 Johnson & Johnson Business Overview

11.1.3 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.1.5 Johnson & Johnson Recent Development

11.2 Sun Pharmaceutical

11.2.1 Sun Pharmaceutical Company Detail

11.2.2 Sun Pharmaceutical Business Overview

11.2.3 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.2.5 Sun Pharmaceutical Recent Development

11.3 CSPC

11.3.1 CSPC Company Detail

11.3.2 CSPC Business Overview

11.3.3 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.3.4 CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.3.5 CSPC Recent Development

11.4 Kinyond

11.4.1 Kinyond Company Detail

11.4.2 Kinyond Business Overview

11.4.3 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.4.4 Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.4.5 Kinyond Recent Development

11.5 Teva

11.5.1 Teva Company Detail

11.5.2 Teva Business Overview

11.5.3 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.5.4 Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.5.5 Teva Recent Development

11.6 Fudan-Zhangjiang

11.6.1 Fudan-Zhangjiang Company Detail

11.6.2 Fudan-Zhangjiang Business Overview

11.6.3 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.6.5 Fudan-Zhangjiang Recent Development

11.7 Zydus Cadila

11.7.1 Zydus Cadila Company Detail

11.7.2 Zydus Cadila Business Overview

11.7.3 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.7.4 Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.7.5 Zydus Cadila Recent Development

11.8 TTY Biopharma

11.8.1 TTY Biopharma Company Detail

11.8.2 TTY Biopharma Business Overview

11.8.3 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.8.4 TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.8.5 TTY Biopharma Recent Development

11.9 Pacira

11.9.1 Pacira Company Detail

11.9.2 Pacira Business Overview

11.9.3 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.9.4 Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.9.5 Pacira Recent Development

11.10 Luye Pharma

11.10.1 Luye Pharma Company Detail

11.10.2 Luye Pharma Business Overview

11.10.3 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.10.4 Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.10.5 Luye Pharma Recent Development

11.11 Leadiant Biosciences

11.11.1 Leadiant Biosciences Company Detail

11.11.2 Leadiant Biosciences Business Overview

11.11.3 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.11.5 Leadiant Biosciences Recent Development

11.12 Ipsen

11.12.1 Ipsen Company Detail

11.12.2 Ipsen Business Overview

11.12.3 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.12.4 Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.12.5 Ipsen Recent Development

11.13 Sayre Therapeutics

11.13.1 Sayre Therapeutics Company Detail

11.13.2 Sayre Therapeutics Business Overview

11.13.3 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.13.5 Sayre Therapeutics Recent Development

11.14 Jazz

11.14.1 Jazz Company Detail

11.14.2 Jazz Business Overview

11.14.3 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.14.4 Jazz Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.14.5 Jazz Recent Development

11.15 Alnylam

11.15.1 Alnylam Company Detail

11.15.2 Alnylam Business Overview

11.15.3 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.15.4 Alnylam Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.15.5 Alnylam Recent Development

11.16 Bausch Health

11.16.1 Bausch Health Company Detail

11.16.2 Bausch Health Business Overview

11.16.3 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.16.4 Bausch Health Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.16.5 Bausch Health Recent Development

11.17 Acrotech Biopharma

11.17.1 Acrotech Biopharma Company Detail

11.17.2 Acrotech Biopharma Business Overview

11.17.3 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.17.5 Acrotech Biopharma Recent Development

11.18 Takeda

11.18.1 Takeda Company Detail

11.18.2 Takeda Business Overview

11.18.3 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.18.4 Takeda Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.18.5 Takeda Recent Development

11.19 Chiesi Farmaceutici

11.19.1 Chiesi Farmaceutici Company Detail

11.19.2 Chiesi Farmaceutici Business Overview

11.19.3 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.19.4 Chiesi Farmaceutici Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.19.5 Chiesi Farmaceutici Recent Development

11.20 Gilead Sciences

11.20.1 Gilead Sciences Company Detail

11.20.2 Gilead Sciences Business Overview

11.20.3 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction

11.20.4 Gilead Sciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)

11.20.5 Gilead Sciences Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details